EQRx to offer new and innovative medicines at affordable prices
Category: #health  By Mateen Dalal  Date: 2020-01-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

EQRx to offer new and innovative medicines at affordable prices

Amidst all the recurring headlines of patients complaining about expensive medicines and treatments, EQRx, a novel biotechnology company, has comes up with plans to create novel, patent-protected drugs at affordable prices.

Reportedly, EQRx is working on re-engineering drug discovery to patient delivery process with an aim to provide a market-based solution for the issue of expensive medicines. EQRx plans to change the medical landscape by leveraging developments in technology and science in order to bring innovative therapies for chronic disorders to patients cost-effectively and more efficiently.

Speaking on the move, Alexis Borisy, Chief Executive Officer and Chairman, EQRx, said that over the past few years, the medical sector has made technological advancements and deepen the understanding of disease biology. However, these new therapeutic approaches are turning out to be way more expensive and are hindering society and people from getting equal benefits from innovation.

Borisy claims that there is a need for market-based solution in order to tackle the issue of rising drug costs. EQRx’s blue-chip team of leaders and founders are delighted to pave the way in redefining innovation and offering high-quality drugs that are affordable to patients.

According to Peter Bach, MD, Co-founder, EQRx, the process of formulating new drugs can be organized with a goal of making them more affordable for patients and society. Nowadays, people with insurance are delaying filling prescriptions due to the high cost of drugs. EQRx eyes on creating affordable new medicines that helps improve people’s health.

Incidentally, EQRx has also managed to secure $200 million from its recent series A funding round. Evidently, the fundraiser saw active participation from ARCH Venture Partners, GV, Section 32, Andreessen Horowitz (a16z) and Casdin Capital, Arboretum Ventures and Nextech.

Dr. Krishna Yeshwant, General Partner at GV, claims that EQRx’s business model would provide a practical approach for developing, rewarding and reinvesting in therapeutics innovation. The company even focuses on delivering these new treatments to a huge network of healthcare systems by the means of cheap pricing.

Source Credit: https://www.citizentribune.com/news/business/eqrx-launches-to-create-innovative-medicines-at-dramatically-lower-prices/article_05e2cf6c-3b92-58ac-a392-4856c819eb7c.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...

Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
Digital wellness startup Mojorcare bags USD 20 Mn in Series A funding
By Mateen Dalal

Mojocare, a wellness and health startup has reportedly raised USD 20.6 million in a Series A round of funding which was led by B Capital Group and saw participation from existing investors including Sequoia India’s Surge, Better Capital, and Ch...

Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
Exponent Energy bags USD 13 million in Lightspeed-led Series A funding
By Mateen Dalal

Bangalore-based Exponent Energy has reportedly secured USD 13 million in a Series A funding round which was spearheaded by Lightspeed Venture Partners. The round also saw participation from existing investors such as 3one4 Capital, YourNest VC, and A...